Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ejh.13493 http://scihub22266oqcxt.onion/10.1111/ejh.13493 32710500!ä!32710500 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Haematol 2020 ; 105 (5): 597-607 Nephropedia Template TP {{tp|p=32710500|t=2020. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies |pdf=|usr=}}{{32710500}} gab.com Text Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies JO: Eur J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=32710500 #FOAvip BACKGROUND: The impact of coronavirus disease 2019 (COVID-19) in haematological patients (HP) has not been comprehensively reported. METHODS: We analysed 39 patients with SARS-CoV-2 infection and haematological malignancies. Clinical characteristics and outcomes were compared to a matched control group of 53 non-cancer patients with COVID-19. Univariate and multivariate analyses were carried out to assess the risk factors associated with poor outcome. RESULTS: The most frequent haematological diseases were lymphoma (30%) and multiple myeloma (30%). Eighty-seven % HP developed moderate or severe disease. Patients with haematological malignancies had a significantly higher mortality rate compared to non-cancer patients (35.9% vs 13.2%; P = .003 (odds ratio 6.652). The worst outcome was observed in chronic lymphocytic leukaemia patients. Only age >70 years and C reactive protein >10 mg/dl at admission were associated with higher risk of death (odds ratio 34.86, P = .003 and 13.56,P = .03). Persistent viral sheddind was detected in 5 HP. Active chemotherapy, viral load at diagnosis and COVID-19 therapy were not predictors of outcome. CONCLUSION: Mortality of COVID-19 is significantly higher in patients with haematological malignancies compared to non-cancer patients. The impact of persistent viral shedding must be considered in order to re-start therapies and maintain infectious control measures. Twit Text FOAVip Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies ????Eur J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=32710500 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32710500 #FOAvip English Wikipedia <ref>{{Cite pmid|32710500}}</ref> Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies #MMPMID32710500 Sanchez-Pina JM; Rodriguez Rodriguez M; Castro Quismondo N; Gil Manso R; Colmenares R; Gil Alos D; Paciello ML; Zafra D; Garcia-Sanchez C; Villegas C; Cuellar C; Carreno-Tarragona G; Zamanillo I; Poza M; Iniguez R; Gutierrez X; Alonso R; Rodriguez A; Folgueira MD; Delgado R; Ferrari JM; Lizasoain M; Aguado JM; Ayala R; Martinez-Lopez J; Calbacho M Eur J Haematol 2020[Nov]; 105 (5): 597-607 PMID32710500show ga BACKGROUND: The impact of coronavirus disease 2019 (COVID-19) in haematological patients (HP) has not been comprehensively reported. METHODS: We analysed 39 patients with SARS-CoV-2 infection and haematological malignancies. Clinical characteristics and outcomes were compared to a matched control group of 53 non-cancer patients with COVID-19. Univariate and multivariate analyses were carried out to assess the risk factors associated with poor outcome. RESULTS: The most frequent haematological diseases were lymphoma (30%) and multiple myeloma (30%). Eighty-seven % HP developed moderate or severe disease. Patients with haematological malignancies had a significantly higher mortality rate compared to non-cancer patients (35.9% vs 13.2%; P = .003 (odds ratio 6.652). The worst outcome was observed in chronic lymphocytic leukaemia patients. Only age >70 years and C reactive protein >10 mg/dl at admission were associated with higher risk of death (odds ratio 34.86, P = .003 and 13.56,P = .03). Persistent viral sheddind was detected in 5 HP. Active chemotherapy, viral load at diagnosis and COVID-19 therapy were not predictors of outcome. CONCLUSION: Mortality of COVID-19 is significantly higher in patients with haematological malignancies compared to non-cancer patients. The impact of persistent viral shedding must be considered in order to re-start therapies and maintain infectious control measures. |Adult[MESH] |Age Factors[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19/blood/*complications/*mortality[MESH] |Case-Control Studies[MESH] |Female[MESH] |Hematologic Neoplasms/blood/*complications[MESH] |Humans[MESH] |Leukemia, Lymphocytic, Chronic, B-Cell/complications[MESH] |Lymphoma/complications[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Myeloma/complications[MESH] |Multivariate Analysis[MESH] |Pandemics[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH]Clinical course and risk factors for mortality from COVID-19 in patien(epmc).pdf DeepDyve Pubget Overpricing